M&As this week: Hansa Medical and Knight Therapeutics
Swedish-based biopharmaceutical company Hansa Medical plans to acquire the rights to cancer immunotherapy using antibody modulating enzymes, through the acquisition of glycobiology therapeutic antibodies developer Immago Biosystems Ltd.
Swedish-based biopharmaceutical company Hansa Medical plans to acquire the rights to cancer immunotherapy using antibody modulating enzymes, through the acquisition of glycobiology therapeutic antibodies developer Immago Biosystems Ltd.
Immago Biosystems is a spinout company of the University of Oxford.
Specialist pharmaceutical company Knight Therapeutics has acquired an additional 15.8% stake in Canadian-based pharmaceutical company Pediapharm, to become an 18.5% stakeholder of the company.
Upon completion of the transaction, Knight Therapeutics will hold 757,500 warrants that are convertible into common shares of Pediapharm at any time until March 2019.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.